MGF (Mechano Growth Factor): Evidence, Mechanism & Status

MGF ("Mechano Growth Factor," IGF-1Ec in humans, IGF-1Eb in rodents) is the locally-expressed, mechanosensitive splice variant of the IGF-1 gene, and the substance sold under the name is the synthetic 24-amino-acid C-terminal E-domain peptide of that variant.12 Its popularity in muscle-building and recovery circles rests on an elegant idea; its proof in humans does not exist. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. MGF and PEG-MGF are not FDA-approved drugs; they are sold as research chemicals not for human use and are prohibited in sport at all times. Dosing figures are reported strictly as seen in the literature and grey-market use for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is MGF and how is it supposed to work?

The IGF-1 gene is alternatively spliced into multiple isoforms that share the same mature IGF-1 core but differ in their C-terminal E-domain. MGF is the IGF-1Ec isoform, produced when a 49-base-pair insert (52-bp in rodents) causes a reading-frame shift, generating a unique 24-amino-acid C-terminal E-peptide absent from the systemic liver isoform IGF-1Ea.21 The marketed "MGF" is the synthetic free 24-mer E-peptide ("MGF-24aa") — chemically a fragment, distinct from full pro-IGF-1Ec. That distinction is load-bearing, because it is disputed whether a free 24-aa MGF peptide is ever cleaved and liberated in the body at all.

The canonical mechanism, all of it preclinical, is a "two-phase" model. Mechanical loading or muscle damage triggers rapid splicing of the IGF-1 gene toward MGF mRNA, before the systemic IGF-1Ea isoform rises.3 The MGF E-peptide is then proposed to activate quiescent satellite (muscle stem) cells and drive their proliferation while suppressing premature differentiation — expanding the myogenic precursor pool — after which mature IGF-1 signals through IGF-1R and PI3K/Akt/mTOR to drive differentiation, fusion and hypertrophy.1 The defining claim is that the E-peptide acts through a receptor distinct from IGF-1R: blocking IGF-1R with an antibody did not abolish MGF-driven myoblast proliferation, and MGF preferentially activates ERK1/2 rather than Akt.12 The exact receptor, however, has never been definitively identified — a major gap. Native MGF is not orally bioavailable and is rapidly degraded by serum proteases, with a reported serum half-life of only about 5-7 minutes, which is the practical reason it is injected locally and the reason the PEGylated analog (PEG-MGF) was created.1213

What is the evidence by indication?

The bottom line up front: there are no human efficacy trials of MGF or PEG-MGF for any indication, and even the preclinical base is internally contradicted by credible null findings. A useful sanity check is to search the registry directly — a query of ClinicalTrials.gov for "mechano growth factor" returns no efficacy study of the marketed E-peptide. Every indication below is therefore animal-model or in-vitro evidence, graded C.

The muscle claim is the most cited and the most fragile. In Goldspink-lab work, intramuscular injection of MGF cDNA into rat tibialis anterior produced a reported roughly 25% increase in mean muscle-fiber cross-sectional area within about two weeks, faster than IGF-1Ea, and in vitro the synthetic E-peptide reportedly increased myoblast number while keeping cells from differentiating.31 But a well-controlled study from Novartis found that synthetic MGF peptide up to 500 ng/ml failed to increase proliferation of C2C12 cells, primary human myoblasts, or primary mouse muscle stem cells, failed to inhibit differentiation, and produced no p-ERK in cardiomyocytes — while mature IGF-1 and full-length IGF-1Eb worked as expected.4 A 2010 review went further, concluding there is inadequate evidence that a discrete MGF peptide is even a genuine in-vivo product of the IGF-1 gene.3

The most coherent positive recent dataset is in connective tissue. Sha et al. (2022) showed in human ACL fibroblasts that injurious stretch suppressed cell area, migration and adhesion via the Rac1/Cdc42/PAK and RhoA/ROCK1 cytoskeletal pathways, and that MGF (10-100 ng/ml) restored fibroblast morphology, migration, adhesion and ROCK1 protein; in a rabbit partial-ACL-transection model MGF dose-dependently improved four-week histological maturation and partially restored fracture strength.5 The MGF E-domain has also been reported to inhibit cardiomyocyte apoptosis and preserve cardiac function in myocardial-infarction models, and to show neuroprotection in animal ischemia models.63 Tellingly, in the growth plate, exogenous MGF peptide did not stimulate chondrocyte proliferation, whereas IGF-1 alone did — a notable negative result that tempers "bone or height growth" claims.2

What doses appear in the literature?

Reported strictly as information, not a protocol. No clinical dosing exists. Preclinical studies dosed cells (typically about 10-100 ng/ml, with both effects and null results seen up to 500 ng/ml) and animals (for example rabbit ACL local doses around 0.1-10 µg/ml) — research exposures, not human regimens.54 Because native MGF's half-life is only minutes, grey-market and community guides describe native MGF as subcutaneous or intramuscular injection directly into or near the specific worked muscle, immediately post-training, precisely because systemic exposure is cleared within minutes.12 Commonly cited vendor and community figures — not trial-derived — are about 100-200 µg per local site for native MGF on training days, and about 200-400 µg, 1-3 times weekly, for the longer-acting PEG-MGF.1413 PEGylation extends the half-life from minutes to a reported several hours up to roughly 48-72 hours depending on PEG size, though no validated human pharmacokinetics exists for either form.15 Material is sold as a lyophilized powder labeled for research use only, with no pharmacopeial standard, sterility or potency assurance.12

How safe is MGF, and what is its 2026 FDA and WADA status?

There is no controlled human safety data; the entire picture is inference from animal and in-vitro work plus anecdote.12 The dominant concern is oncologic and is more than hypothetical: MGF is a pro-proliferative, anti-apoptotic growth factor, and the MGF E-peptide promoted proliferation, migration and invasion of osteosarcoma cells in vitro, was overexpressed in more-malignant osteosarcoma lines, and altered cyclin D1, MMP-9, VEGF and caspase-3.7 Because it can drive quiescent progenitor cells into the cell cycle, a theoretical concern is activation of dormant cancer cells, compounded by the IGF axis's epidemiologic association with cancer risk. Other reported effects are injection-site reactions and theoretical immunogenicity to a synthetic or PEGylated construct.13 Active or prior malignancy, pre-cancerous lesions, and pregnancy or lactation are the clearest precautionary exclusions, and material sold as an unregulated research chemical carries an independent hazard of unknown identity, purity, sterility and sequence.7

On the regulatory side, MGF and PEG-MGF are not FDA-approved for any use. In September 2023 the FDA placed Pegylated Mechano Growth Factor into 503A Category 2 ("bulk drug substances that raise significant safety concerns"), effectively barring pharmacy compounding.10 On or around April 15, 2026 the FDA republished its interim 503A Bulks List and identified PEG-MGF among five peptide substances to be removed from Category 2 and referred for advisory-committee consultation, with the Pharmacy Compounding Advisory Committee (PCAC) slated to convene before the end of February 2027.11 The critical point: removal from Category 2 does not by itself make PEG-MGF eligible for compounding — its status remains unresolved pending PCAC.10

For athletes the picture is unambiguous. "Mechano Growth Factors (MGFs)" are explicitly named under section S2.3 (Growth Factors and Growth Factor Modulators) of the 2026 WADA Prohibited List, prohibited at all times, in and out of competition, and classified as non-Specified, which carries the strictest sanctions.89 MGF is not a DEA-scheduled controlled substance, but any WADA-tested athlete should treat it as banned, with detection an anti-doping rule violation and no therapeutic-use rationale.

Bottom line. MGF is one of the most mechanistically compelling but clinically unproven peptides in the muscle-repair space. Three facts dominate an honest verdict: there are zero human trials of any kind, so every benefit is Grade C or D, never A or B; the preclinical base is genuinely contested, with a controlled study finding no myoblast activity up to 500 ng/ml and a review questioning whether a free MGF peptide even exists in vivo; and the standout safety signal is oncologic. Add the minutes-long half-life, the research-chemical supply chain, an unresolved FDA compounding status, and an unambiguous WADA ban, and the practical conclusion is clear — MGF is an interesting research molecule and a regulatory and anti-doping liability, hyped well beyond its evidence. Regulatory facts here are current as of June 2026; the PCAC outcome was pending at the time of writing and should be re-verified after it convenes.